8 recruiting, 3 completed, 2 terminated. 13 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 13 | Recruiting 8, Completed 3, Terminated 2 |
Follow Multiple System Atrophy: new trials by email Literature Review of Multiple System Atrophy trials Research Report on Multiple System Atrophy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Test-retest Trial With [11C]MODAG-005 in PD or MSA and AMHC - Pilot Phase [11C]MODAG-005 - Parkinson Disease (PD), MSA - Multiple System Atrophy | Early Phase 1 | Recruiting | MODAG GmbH | 9 | 2026-07-29 | 2026-07-31 |
| Expansion Study of ALT001 in Patients With Multiple System Atrophy ALT001 - Multiple System Atrophy | Early Phase 1 | Recruiting | yilong Wang | 60 | 2026-06-15 | 2026-09-09 |
| The Study of Safety and Preliminary Efficacy of ALT001 in Patients With MultIple System Atrophy-Cerebellar Type ALT001 - Multiple System Atrophy - Cerebellar Subtype (MSA-C) | Early Phase 1 | Recruiting | yilong Wang | 20 | 2026-06-10 | 2026-09-09 |
| Evaluation of the Pharmacokinetics, Biodistribution and Radiation Dosimetry of [18F]MODAG-009 Positron Emission Tomography (PET) Radiotracers in Adult Healthy Volunteers [¹⁸F]MODAG-009 PET Imaging - Healthy Adult | Early Phase 1 | Recruiting | MODAG GmbH | 6 | 2026-05-27 | 2026-06-04 |
| Evaluation of [¹⁸F]MODAG-009 PET Imaging in Synucleinopathies [¹⁸F]MODAG-009 PET imaging - Multiple System Atrophy (MSA), Healthy Adult | Early Phase 1 | Recruiting | MODAG GmbH | 13 | 2026-05-13 | 2026-06-10 |
| The Study of Safety and Preliminary Efficacy of Aleeto in Patients With MultIple System Atrophy Aleeto - Multiple System Atrophy - Parkinsonian Subtype (MSA-P), Multiple System Atrophy, MSA | Early Phase 1 | Recruiting | Beijing Tiantan Hospital | 20 | 2025-05-31 | 2025-09-03 |
| [18F]ACI-15916 PET in α-synucleinopathies [18F]ACI-15916 - Parkinson's Disease (PD), Multiple System Atrophy (MSA) | Early Phase 1 | Recruiting | AC Immune SA | 46 | 2025-03-20 | 2026-10-28 |
| PET Imaging Evaluation of [11C]SY08 C11-SY08 - Parkinson's Disease, Multiple System Atrophy | Early Phase 1 | Recruiting | Massachusetts General Hospital | 40 | 2024-05-01 | 2025-12-24 |
| Effect of Verdiperstat on Microglial Activation in Well-characterized MSA Patients [F-18]PBR06, Verdiperstat - Multiple System Atrophy, Multiple System Atrophy, Cerebellar Variant | Early Phase 1 | Completed | Brigham and Women's Hospital | 19 | 2020-12-30 | 2022-08-19 |
| Study to Evaluate a Potential PET Radioligand for Imaging Alpha-synuclein Deposits in the Brain [18F]MNI-1216 - Alpha-Synucleinopathy, Parkinson's Disease | Early Phase 1 | Completed | Invicro | 12 | 2020-12-24 | 2025-02-19 |
| Effect of Midodrine vs Abdominal Compression on Cardiovascular Risk Markers in Autonomic Failure Patients Midodrine, Placebo pill, Abdominal compression - Neurogenic Orthostatic Hypotension, Autonomic Failure | Early Phase 1 | Completed | Vanderbilt University Medical Center | 31 | 2020-11-09 | 2026-08-07 |
| Blood Pressure Lowering Effects of Angiotensin-(1-7) in Primary Autonomic Failure Angiotensin-(1-7), Saline - Autonomic Nervous System Disorders, Pure Autonomic Failure | Early Phase 1 | Terminated | Vanderbilt University Medical Center | 7 | 2016-02-01 | 2021-01-12 |
| Water and Sudafed in Autonomic Failure Pseudoephedrine + 480 ml water, Pseudoephedrine + 50 ml water, Placebo + 480 ml water (optional) - Shy-Drager Syndrome, Multiple System Atrophy | Early Phase 1 | Terminated | Vanderbilt University | 35 | 2014-10-01 | 2021-05-05 |
Parkinson Disease (7) · Lewy Body Disease (3) · Pure Autonomic Failure (3) · Shy-Drager Syndrome (3) · Autonomic Nervous System Diseases (1) · Hypertension (1) · Multiple system atrophy (MSA) with orthostatic hypotension (1) · Nerve Degeneration (1) · Synucleinopathies (1) · Thyroid Dyshormonogenesis 2A (1)
Basal Ganglia Diseases (13) · Brain Diseases (13) · Central Nervous System Diseases (13) · Movement Disorders (13) · Nervous System Diseases (13) · Primary Dysautonomias (13) · Autonomic Nervous System Diseases (12) · Neurodegenerative Diseases (12) · Synucleinopathies (11) · Parkinsonian Disorders (7) · Cardiovascular Diseases (3) · Dementia (3) · Hypotension (3) · Mental Disorders (3) · Neurocognitive Disorders (3)
Acetates (1) · Drinking Water (1) · Midodrine (1) · Pseudoephedrine (1) · Saline Solution (1) · Sodium Chloride (1) · Sugars (1) · Water (1) · angiotensin I (1-7) (1)
MODAG GmbH (3) · Vanderbilt University Medical Center (2) · yilong Wang (2) · AC Immune SA (1) · Beijing Tiantan Hospital (1) · Brigham and Women's Hospital (1) · Invicro (1) · Massachusetts General Hospital (1) · Vanderbilt University (1)
United States (8) · China (3) · Germany (1) · Sweden (1)
Tao Feng (2) · Yilong Wang (2) · Andrea Varrone, Prof. (1) · David Russell, MD (1) · Emily M Garland, PhD, MSCI (1) · Italo Biaggioni, MD (1) · Luis Okamoto, MD (1) · Neha Prakash, MBBS (1) · Tao Feng, M.D. (1) · Tarun Singhal, MD (1) · Vikram Khurana, MD, PhD (1) · Yilong Wang, M.D. (1)
2023 (1), P01HL056693 (1), R01HL144568 (1), UL1TR000445 (1)